Allogene Therapeutics Stock Price, News & Analysis

Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report its third quarter 2022 financial results on November 2, 2022, after the market closes. A live audio webcast and conference call will follow at 2:00 PM PT/5:00 PM ET. Investors can access the live event on the company's website, with a replay available for 30 days. Allogene Therapeutics is dedicated to developing allogeneic CAR T cell products for cancer treatments, aiming to provide accessible cell therapy solutions on-demand.

Allogene Therapeutics (ALLO) has launched the CAR T Together initiative to enhance access to allogeneic CAR T therapies for cancer patients. A recent survey showed that only 50% of eligible patients receive current autologous CAR T treatments, with significant delays in access, as 40% wait three to six months. The initiative aims to accelerate clinical trials for 'off-the-shelf' CAR T products, addressing the challenges of patient demand and manufacturing capacity.

Allogene Therapeutics has initiated the Phase 2 ALPHA2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma patients, aiming to demonstrate the efficacy of a single-dose regimen paired with ALLO-647. Supported by promising Phase 1 data, the trial will enroll around 100 patients, focusing on the objective response rate as its primary endpoint. The company also plans to launch the EXPAND trial to assess the contribution of ALLO-647. The FDA recently granted Regenerative Medicine Advanced Therapy designation to ALLO-501A, underscoring its potential in addressing unmet treatment needs.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a biotechnology company focused on allogeneic CAR T (AlloCAR T™) products for cancer, announced its participation in the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 6:30 AM Pacific Time. Management will present insights about its pipeline of 'off-the-shelf' CAR T cell candidates aimed at improving availability and scalability of cell therapy. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterwards.

Allogene Therapeutics (ALLO) announced significant developments in its clinical initiatives, including anticipated U.S. FDA clearance for the Phase 2 pivotal trial of ALLO-501A targeting relapsed/refractory large B cell lymphoma (LBCL). This trial could be a first for allogeneic CAR T therapies. The company’s manufacturing facility, Cell Forge 1, is expected to produce approximately 20,000 doses annually. As of June 30, 2022, Allogene reported $686 million in cash and a net loss of $74.8 million for Q2 2022, with increased spending expected in the second half of the year.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences. These include the 42nd Annual Canaccord Genuity Growth Conference on August 11, 2022, the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, and the Baird 2022 Global Healthcare Conference on September 13, 2022. Allogene is focused on developing allogeneic CAR T products for cancer treatment. Webcasts of the presentations will be available on the company’s website.

Allogene Therapeutics (Nasdaq: ALLO) will announce its second quarter 2022 financial results on August 9, 2022, after market close. A conference call and live audio webcast will follow at 2 PM PT/5 PM ET. The webcast can be accessed on the company's website, with a replay available for 30 days. Allogene focuses on developing AlloCAR T™ products to provide accessible cell therapy for cancer patients. This initiative aims to enhance the reliability and scalability of treatment options.

Allogene Therapeutics (Nasdaq: ALLO) has appointed Stephen L. Mayo, Ph.D., an expert in computational protein design, to its Board of Directors. Mayo has extensive experience in both academia and the biopharmaceutical sector, which is expected to benefit Allogene as it advances its AlloCAR T product pipeline. Mayo's background includes leadership roles at Caltech and co-founding several biotech companies. His appointment is aimed at enhancing the company's ability to deliver innovative cell therapies to cancer patients.

Allogene Therapeutics (Nasdaq: ALLO) announced the FDA granted RMAT designation to ALLO-501A for patients with relapsed/refractory large B cell lymphoma (LBCL). This recognition follows positive results from the ALPHA2 trial, demonstrating safety and durable responses. Treatment initiation occurs within two days, enhancing patient access. The company plans to start a Phase 2 pivotal trial in mid-2022. The RMAT designation aims to expedite the development of ALLO-501A, which aims to meet critical patient needs lacking effective therapies.